Clinical trials: Carcinoma, Thymic
Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/ Phaeochromocytoma
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
This study is a phase 2, open, single-site trial. The primary objective of this study is to prospectively evaluate the safety and efficacy in participants treated with Lu-177 DOTATATE (Lutathera) in unresectable or metastatic…
- Conditions
- Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/ Phaeochromocytoma, Medullary Thyroid Carcinoma, Those Requiring Repeat Peptide Receptor Radionuclide Therapy
- Trial name
- NCT06121271
- Testing
- Lu-177 DOTATATE (Lutathera®)
- Volunteers
- 110 people
- Sponsor
- University College, London
Cardiotoxicity, Pulmonary Toxicity
Study on Proton Radiotherapy of Thymic Malignancies
This is a multicentre non-randomized phase II study of proton beam radiotherapy in patients with thymic epithelial tumours (i.e.
- Conditions
- Cardiotoxicity, Pulmonary Toxicity, Thymus Neoplasms
- Trial name
- PROTHYM (NCT04822077)
- Testing
- Proton radiation
- Where
- 3 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- Ass. Prof. Jan Nyman
Thymoma and Thymic Carcinoma
Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma
This study is designed to investigate whether adjuvant radiochemotherapy after incomplete resection has a better survival than adjuvant radiotherapy for thymoma or thymic carcinoma.
- Trial name
- NCT02633514
- Testing
- Cisplatin, Etoposide, radiotherapy
- Where
- China
- Sponsor
- Fudan University
Thymoma, Thymic Carcinoma
Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage
Background: Cisplatin-containing chemotherapy is the standard treatment for advanced tumors of the thymus that cannot be removed surgically.
- Trial name
- NCT00589290
- Testing
- Belinostat (PDX101)
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Thymic Carcinoma
Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy
Indication: Patients with advanced recurrent or metastatic thymic carcinoma. Phase IIa (China only):Approximately 6 patients. Phase IIb (China only):Approximately 54 patients.
- Trial name
- NCT07824505
- Testing
- lucitanib 15 mg QD, lucitanib 10 mg QD
- Where
- 16 sites in China
- Volunteers
- 74 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Pancreas Cancer, Ovarian Cancer
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
This is a single arm, single-stage, phase II trial to evaluate the activity of Regorafenib in patients with metastatic solid tumors (pancreatic cancer, ovarian cancer, melanoma, sarcoma, thymoma (type B2 - B3) and thymic…
- Conditions
- Pancreas Cancer, Ovarian Cancer, Melanoma, Sarcoma
- Trial name
- RESOUND (NCT02307500)
- Testing
- Regorafenib
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Istituto Clinico Humanitas
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Background: Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors
- Trial name
- NCT02146170
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- National Cancer Institute (NCI)
Thymoma, Thymic Carcinoma
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
Background: Tumors of the thymus are rare and can be treated with surgery, but it is often difficult to determine whether a thymic tumor is malignant based on biopsy alone and the long-term survival rate is less than 50 percent.
- Trial name
- NCT01100944
- Testing
- PXD101with cisplatin+doxorubicin+cyclophosphamide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Thymic Carcinoma
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations…
- Trial name
- NCT06019468
- Testing
- Envolizumab combined with radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Thyroid Nodule, Thyroid Cancer
Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer
The purpose of this registry is to collect uniform genomics-centered data on patients with nodular thyroid disease and cancer in a prospective fashion.
- Conditions
- Thyroid Nodule, Thyroid Cancer, Thyroid Diseases, Thymic Carcinoma
- Trial name
- NCT03170804
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Aventura Hospital and Medical Center
Thymic Carcinoma
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
The goal of this clinical trial is to learn if drug Sac-TMT works to treat Thymic Carcinoma. It will also learn about the safety of Sac-TMT.
- Trial name
- NCT07324629
- Testing
- Sacituzumab tirumotecan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Background: The current standard of care for advanced lung cancer and cancers of the thymus consists primarily of chemotherapy treatment.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic
- Trial name
- NCT01306045
- Testing
- AZD6244, MK-2206, Lapatinib
- Where
- United States
- Volunteers
- 647 people
- Sponsor
- National Cancer Institute (NCI)
Thymoma Type B3, Thymic Carcinoma
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
The aim of the phase II Nivothym study is to collect data on activity and toxicity of nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously received a first platinum-based chemotherapy.
- Trial name
- NIVOTHYM (NCT03134118)
- Testing
- Nivolumab
- Where
- 20 sites in Belgium, France and 4 more
- Volunteers
- 55 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Unresectable Thymic Carcinoma
A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas
This is a non-randomized, open-label, investigator-initiated phase II clinical trial designed to evaluate the efficacy and safety of sacituzumab tirumotecan (hereafter referred to as sac-TMT) in patients with unresectable thymic…
- Trial name
- XANTHOS (NCT07750353)
- Testing
- Sacituzumab Tirumotecan (Sac-TMT)
- Where
- 3 sites in Japan
- Volunteers
- 35 people
- Sponsor
- National Cancer Center, Japan
Thymoma, Thymus Neoplasms
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
Background: Sunitinib is drug that is approved for treating various types of cancers, including kidney cancers. However, it has not been approved to treat cancers of the thymus.
- Trial name
- NCT01621568
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Thymoma, Advanced Thymic Epithelial Tumour
Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma
The aim of the study is to determine the efficacy of selinexor in adults with TETs determined by overall response rate (RECIST 1.1) in two parallel cohorts of patients with advanced thymomas or thymic carcinomas.
- Trial name
- TET-SEL (NCT03466827)
- Testing
- Selinexor
- Where
- 4 sites in Denmark, France
- Volunteers
- 25 people
- Sponsor
- Morten Mau-Soerensen
NSCLC, Esophageal Squamous Cell Carcinoma
Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer
This study is an observation, single center study to evaluate the alternations and prognostic value of peripheral blood lymphocyte (PBL) in patients diagnosed with thoracic cancers, including lung cancer, esophageal squamous cell…
- Conditions
- NSCLC, Esophageal Squamous Cell Carcinoma, Thymic Epithelial Tumor
- Trial name
- NCT04522687
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Cancer Hospital, China
Thymic Epithelial Tumor, Thymic Carcinoma
Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors
Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection.
- Conditions
- Thymic Epithelial Tumor, Thymic Carcinoma, Thymoma, Thymoma and Thymic Carcinoma
- Trial name
- INTHYM (NCT06301945)
- Testing
- Artificial Intelligence Diagnostics, Recurrence Prediction Tool
- Where
- Netherlands
- Volunteers
- 1,020 people
- Sponsor
- Erasmus Medical Center
Thymus Cancer, Thymoma
Molecular Analysis of Thoracic Malignancies
A research study to learn about the biologic features of cancer development, growth, and spread. We are studying components of blood, tumor tissue, normal tissue, and other fluids, such as urine, cerebrospinal fluid, abdominal or…
- Conditions
- Thymus Cancer, Thymoma, Thymic Carcinoma, Lung Cancer
- Trial name
- NCT01385722
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Stanford University